Essential medicine lists are a tool for balancing public health needs with pharmaceutical market realities. Comment with reference to India and WHO frameworks.

An essential medicines list identifies drugs that satisfy the priority healthcare needs of a population, selected on evidence of efficacy, safety and comparative cost-effectiveness. Such lists are genuinely a balancing instrument — they secure affordability without abolishing the market — but the balance holds only if revision keeps pace with therapeutic advance.

How the lists serve public health need

• WHO's Model List, revised on a biennial cycle, is the global benchmark; its 24th edition (2025) carries over 520 medicines [4].
• The 25th Expert Committee (Geneva, May 2025) assessed 59 applications on efficacy, safety and cost-effectiveness, adding cancer therapies and GLP-1 agonists for type-2 diabetes with cardiovascular or renal comorbidity [3].
• India's NLEM 2022, framed by the Standing National Committee on Medicines (SNCM, constituted 2018) and notified on 13.09.2022, lists 384 medicines across 27 therapeutic categories, adding 34 and dropping 26 [1].

How they accommodate market realities

• Listing is not nationalisation: it triggers ceiling prices fixed by the NPPA under the Drug Price Control Order, leaving manufacture, competition and non-listed drugs to the market.
• Price re-fixation under NLEM 2022 yielded estimated annual savings of about ₹3,788 crore to patients — relief delivered through regulated pricing rather than subsidy [2].
• Selective coverage protects industry viability and R&D incentives while capping the drugs that matter most for out-of-pocket spending.

Where the balance slips

• India's list is unrevised since 2022, while WHO has issued two updates (2023, 2025) [3][4]; newer essential therapies therefore stay outside price control.
• Revision rests on administrative discretion, not a statutory timetable — civil society has urged early revision [5].

Essential medicine lists thus reconcile equity with market efficiency, but the reconciliation is dynamic, not one-time. Institutionalising a fixed two-year revision cycle for NLEM, with a standing SNCM secretariat and transparent stakeholder consultation, would align India with the WHO benchmark and advance both Article 21's promise of accessible healthcare and SDG-3's universal health coverage target.